SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Got ...

They don't have the most exciting businesses, but they have a lot to offer nonetheless.Healthcare never sleeps. There is always demand for medical services, regardless of the state of the economy. Companies that offer these necessary goods and are innovative enough to keep up with the changing trends in the sector tend to last. That describes Johnson & Johnson (JNJ 0.12%) and Medtronic (MDT -0.15%) well. Both are among the largest healthcare companies in the world, have proven innovative abilities, and have ...

文章核心观点 - 2024年第二季度财报季已经全面展开,预计标普500指数将再次实现盈利增长[1] - 下周将有多家知名公司如Netflix、台积电和强生公司发布财报,值得关注[2] Netflix - Netflix的订阅者数量指标将是关键,公司将从2025年第一季度开始不再报告季度会员数[4] - 最新一季度Netflix的总订阅用户达到2.696亿,同比增长16%,连续4个季度超出预期[5] - Netflix的盈利能力和营收增长都有所改善,预计本季度每股收益将增长43%,收入增长17%[6] 台积电 - 受益于人工智能热潮,台积电股价今年已涨超80%,大幅跑赢大盘[9] - 本季度每股收益预计增长20%至1.37美元,收入预计增长5%至202亿美元,同比增29%[10] - 投资者对台积电未来增长前景乐观,估值有所扩张,但PEG仍在合理区间[11] - 台积电近期还宣布将派息提高10%,深受重视收益的投资者青睐[12] 强生公司 - 强生公司股价在过去3年中一直横盘整理,下跌4%,但盈利表现一直较为出色[13] - 本季度每股收益预计为2.71美元,较4月中旬的预期下调1%[15][17] - 收入预计同比下降12%至224亿美元[16]

The upcoming report from Johnson & Johnson (JNJ) is expected to reveal quarterly earnings of $2.71 per share, indicating a decline of 3.2% compared to the year-ago period. Analysts forecast revenues of $22.38 billion, representing a decrease of 12.3% year over year.Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the co ...

Recession-proof stocks offer investors a safe harbor to shield their portfolios from downside risk.The stock market has cooled off following its AI-powered surge for the last two years. While most experts have called for a soft economic landing, the looming possibility of a recession next year complicates the investing landscape. Hence, the focus is now more on resilient and operationally efficient companies that can hold their own during economic downturns.These businesses boast robust fundamentals thanks ...

MEDITERRANEAN/iStock Unreleased via Getty ImagesIntroduction Pharmaceutical and medical devices giant Johnson & Johnson (NYSE:JNJ) will release its second quarter results on Wednesday, July 17 at 8:30 a.m. Eastern Time. While in my last article I previewed the first quarter results and shared my view on the then-announced acquisition of Shockwave Medical, Inc., the topic of this earnings preview focuses on JNJ's earnings quality. Johnson & Johnson is known for its clockwork-like track record, meeting an ...

In an era where some investors prioritize stable income and reliable returns, artificial intelligence (AI) has identified three standout dividend stocks poised to shine in the latter half of 2024. These companies have built a track record of resilience, consistent performance, and a commitment to rewarding shareholders through reliable dividend distributions.In this line, Finbold turned to OpenAI’s latest and most advanced AI platform, ChatGPT-4o, to gather insights on the must-have dividend stocks for the ...

JHVEPhoto In my last article, I called Johnson & Johnson (NYSE:JNJ) (NEOE:JNJ:CA) a very cautious “Buy” but since my last article Johnson & Johnson continued to decline further and the stock lost about 9% in value during the last 10 months. Especially when comparing the performance to the S&P 500 (SPY) which increased 23% in the same timeframe, we have to see Johnson & Johnson rather as a disappointment. Johnson & Johnson is not really declining steeply, but the stock is slowly creeping lower and has re ...

CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy RARITAN, N.J., July 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone ( ...

文章核心观点 - 收益型投资者可以在任何市场环境中找到大量机会 [1] - 股息股票是一种很好的方式,可以为投资组合增加现金流,并随时间推移帮助复合整体收益 [1] - 投资股息股票时,需要确保公司有强大的基本面和资产负债表,以支持和增长支付的股息 [2] 公司分析 Johnson & Johnson - 已连续62年每年支付并增加股息,是"股息之王"中的佼佼者 [4] - 股息收益率为3.4%,是标普500平均水平的两倍以上 [5] - 过去10年股息年均增长6%,派息率仅30% [5] - 股价表现相对较弱,主要受到与其滑石粉产品相关的诉讼和潜在负债的影响 [6] - 公司拥有260亿美元现金,可用于管理诉讼并维持对股东的承诺 [6] - 公司营收860亿美元,利润170亿美元,自由现金流240亿美元 [7] - 去年将消费品业务分拆,专注于更快增长的制药和医疗器械业务 [8] - 长期投资者可能会发现该公司是一个有吸引力的投资机会 [9] 可口可乐 - 已连续62年每年增加股息,股息收益率约3% [10] - 过去5年和10年的总回报分别为46%和108% [10] - 在美国市场占据46%的碳酸饮料市场份额 [11] - 过去12个月利润110亿美元,营收460亿美元,利润率23% [12] - 派息率74%,仍处于可控水平,过去10年股息年均增长5% [12] - 过去12个月经营现金流120亿美元,自由现金流110亿美元 [13] - 尽管受到汇率和宏观环境波动的影响,但其股息承诺和资产负债表实力仍彰显了这家公司的抗风险能力 [13] - 长期持有型投资者可能会对可口可乐感兴趣 [14]